Hims & Hers Health, Inc.
HIMS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -3.22 | -4.82 | 0.40 | -0.77 |
| FCF Yield | 0.71% | -0.62% | 0.76% | 1.12% |
| EV / EBITDA | 455.33 | 298.61 | 95.95 | 206.30 |
| Quality | ||||
| ROIC | 0.47% | 2.15% | 7.70% | 4.45% |
| Gross Margin | 73.80% | 76.39% | 73.50% | 76.81% |
| Cash Conversion Ratio | 9.43 | -0.45 | 2.20 | 3.32 |
| Growth | ||||
| Revenue 3-Year CAGR | 40.77% | 41.50% | 42.52% | 40.98% |
| Free Cash Flow Growth | 231.66% | -238.72% | -15.88% | -25.05% |
| Safety | ||||
| Net Debt / EBITDA | 25.83 | -2.16 | -3.18 | -8.49 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.48 | 0.91 | 2.04 | 1.73 |
| Cash Conversion Cycle | -46.80 | 26.85 | -17.95 | -20.44 |